TY - JOUR
T1 - Clinical, neuroimaging, and molecular spectrum of TECPR2-associated hereditary sensory and autonomic neuropathy with intellectual disability
AU - Neuser, Sonja
AU - Brechmann, Barbara
AU - Heimer, Gali
AU - Brösse, Ines
AU - Schubert, Susanna
AU - O'Grady, Lauren
AU - Zech, Michael
AU - Srivastava, Siddharth
AU - Sweetser, David A.
AU - Dincer, Yasemin
AU - Mall, Volker
AU - Winkelmann, Juliane
AU - Behrends, Christian
AU - Darras, Basil T.
AU - Graham, Robert J.
AU - Jayakar, Parul
AU - Byrne, Barry
AU - Bar-Aluma, Bat El
AU - Haberman, Yael
AU - Szeinberg, Amir
AU - Aldhalaan, Hesham M.
AU - Hashem, Mais
AU - Al Tenaiji, Amal
AU - Ismayl, Omar
AU - Al Nuaimi, Asma E.
AU - Maher, Karima
AU - Ibrahim, Shahnaz
AU - Khan, Fatima
AU - Houlden, Henry
AU - Ramakumaran, Vijayalakshmi S.
AU - Pagnamenta, Alistair T.
AU - Posey, Jennifer E.
AU - Lupski, James R.
AU - Tan, Wen Hann
AU - ElGhazali, Gehad
AU - Herman, Isabella
AU - Muñoz, Tatiana
AU - Repetto, Gabriela M.
AU - Seitz, Angelika
AU - Krumbiegel, Mandy
AU - Poli, Maria Cecilia
AU - Kini, Usha
AU - Efthymiou, Stephanie
AU - Meiler, Jens
AU - Maroofian, Reza
AU - Alkuraya, Fowzan S.
AU - Abou Jamra, Rami
AU - Popp, Bernt
AU - Ben-Zeev, Bruria
AU - Ebrahimi-Fakhari, Darius
N1 - Publisher Copyright:
© 2021 The Authors. Human Mutation published by Wiley Periodicals LLC
PY - 2021/6
Y1 - 2021/6
N2 - Bi-allelic TECPR2 variants have been associated with a complex syndrome with features of both a neurodevelopmental and neurodegenerative disorder. Here, we provide a comprehensive clinical description and variant interpretation framework for this genetic locus. Through international collaboration, we identified 17 individuals from 15 families with bi-allelic TECPR2-variants. We systemically reviewed clinical and molecular data from this cohort and 11 cases previously reported. Phenotypes were standardized using Human Phenotype Ontology terms. A cross-sectional analysis revealed global developmental delay/intellectual disability, muscular hypotonia, ataxia, hyporeflexia, respiratory infections, and central/nocturnal hypopnea as core manifestations. A review of brain magnetic resonance imaging scans demonstrated a thin corpus callosum in 52%. We evaluated 17 distinct variants. Missense variants in TECPR2 are predominantly located in the N- and C-terminal regions containing β-propeller repeats. Despite constituting nearly half of disease-associated TECPR2 variants, classifying missense variants as (likely) pathogenic according to ACMG criteria remains challenging. We estimate a pathogenic variant carrier frequency of 1/1221 in the general and 1/155 in the Jewish Ashkenazi populations. Based on clinical, neuroimaging, and genetic data, we provide recommendations for variant reporting, clinical assessment, and surveillance/treatment of individuals with TECPR2-associated disorder. This sets the stage for future prospective natural history studies.
AB - Bi-allelic TECPR2 variants have been associated with a complex syndrome with features of both a neurodevelopmental and neurodegenerative disorder. Here, we provide a comprehensive clinical description and variant interpretation framework for this genetic locus. Through international collaboration, we identified 17 individuals from 15 families with bi-allelic TECPR2-variants. We systemically reviewed clinical and molecular data from this cohort and 11 cases previously reported. Phenotypes were standardized using Human Phenotype Ontology terms. A cross-sectional analysis revealed global developmental delay/intellectual disability, muscular hypotonia, ataxia, hyporeflexia, respiratory infections, and central/nocturnal hypopnea as core manifestations. A review of brain magnetic resonance imaging scans demonstrated a thin corpus callosum in 52%. We evaluated 17 distinct variants. Missense variants in TECPR2 are predominantly located in the N- and C-terminal regions containing β-propeller repeats. Despite constituting nearly half of disease-associated TECPR2 variants, classifying missense variants as (likely) pathogenic according to ACMG criteria remains challenging. We estimate a pathogenic variant carrier frequency of 1/1221 in the general and 1/155 in the Jewish Ashkenazi populations. Based on clinical, neuroimaging, and genetic data, we provide recommendations for variant reporting, clinical assessment, and surveillance/treatment of individuals with TECPR2-associated disorder. This sets the stage for future prospective natural history studies.
KW - Human Phenotype Ontology
KW - TECPR2
KW - neurodevelopmental disorder
KW - sensory autonomic neuropathy
KW - spastic paraplegia
UR - http://www.scopus.com/inward/record.url?scp=85105550925&partnerID=8YFLogxK
U2 - 10.1002/humu.24206
DO - 10.1002/humu.24206
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 33847017
AN - SCOPUS:85105550925
SN - 1059-7794
VL - 42
SP - 762
EP - 776
JO - Human Mutation
JF - Human Mutation
IS - 6
ER -